NASDAQ:ALMR Alamar Biosciences (ALMR) Stock Price, News & Analysis $28.68 -1.83 (-6.00%) As of 11/19/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Alamar Biosciences Stock (NASDAQ:ALMR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Alamar Biosciences alerts:Sign Up Key Stats Today's Range$28.53▼$31.4850-Day Range$23.52▼$38.1352-Week Range$18.84▼$39.61Volume326,540 shsAverage Volume733,057 shsMarket Capitalization$1.99 billionP/E RatioN/ADividend YieldN/APrice Target$33.00Consensus RatingModerate Buy Company Overview Alamar Biosciences is a life sciences tools company that develops technologies for measuring proteins in biological samples. Its products are designed to help researchers study disease biology and support the development of tools for earlier disease detection and precision medicine. The company’s offerings include its NULISA platform, which enables sensitive measurement of multiple proteins, and the ARGO HT system, an automated instrument for running assays. Its applications include research into neurodegenerative diseases, cancer and inflammation. Founded in 2018 and headquartered in Fremont, California, Alamar serves researchers and other organizations working in life sciences and biomedical research.AI Generated. May Contain Errors. Read More Alamar Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreALMR MarketRank™: 2.82420154185 of 5 starsAlamar Biosciences scored higher than 56% of companies evaluated by MarketBeat, and ranked 389th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.9 / 5Analyst RatingModerate Buy Consensus RatingAlamar Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialAlamar Biosciences has a consensus price target of $33.00, representing about 15.1% upside from its current price of $28.68.Amount of Analyst CoverageAlamar Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Alamar Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Alamar Biosciences are expected to grow in the coming year, from ($1.29) to ($1.00) per share.Price to Book Value per Share RatioAlamar Biosciences has a P/B Ratio of 6.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.23% of the float of Alamar Biosciences has been sold short.Short Interest Ratio / Days to CoverAlamar Biosciences has a short interest ratio ("days to cover") of 3.27, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alamar Biosciences has recently decreased by 16.19%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlamar Biosciences does not currently pay a dividend.Dividend GrowthAlamar Biosciences does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.74 News SentimentAlamar Biosciences has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Alamar Biosciences this week, compared to 4 articles on an average week.Search Interest7 people have searched for ALMR on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Alamar Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alamar Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $47,503,514.00 in company stock.Percentage Held by InstitutionsAlamar Biosciences has minimal institutional ownership at this time.Read more about Alamar Biosciences' insider trading history. Receive ALMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alamar Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALMR Stock News HeadlinesAlamar Biosciences Announces 46 NULISA Presentations at CTAD 2026 Highlighting Alzheimer’s Disease ResearchNovember 16, 2026 | quiverquant.comQAlamar Biosciences Highlights NULISA Data in 46 Presentations at CTAD 2026, Including 10 Oral PresentationsNovember 16, 2026 | globenewswire.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out. | Weiss Ratings (Ad)Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Corporate Gp Vi Ltd. Qiming Sells 100,117 Shares of StockNovember 15, 2026 | insidertrades.comAlamar Biosciences, Inc. (ALMR) Presents at 2026 UBS Global Healthcare Conference TranscriptNovember 10, 2026 | seekingalpha.comAlamar Biosciences (NASDAQ:ALMR) Major Shareholder Sells 111,313 Shares of Company StockNovember 6, 2026 | insidertrades.comInsider Selling: Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Sells $1,310,871.20 in StockNovember 4, 2026 | insidertrades.comAlamar Biosciences (NASDAQ:ALMR) Major Shareholder Corporate Gp Vi Ltd. Qiming Sells 84,894 Shares of StockOctober 30, 2026 | insidertrades.comSee More Headlines ALMR Stock Analysis - Frequently Asked Questions How have ALMR shares performed this year? Alamar Biosciences' stock was trading at $22.00 on April 17, 2026. Since then, ALMR stock has increased by 30.4% and is now trading at $28.68. How were Alamar Biosciences' earnings last quarter? Alamar Biosciences, Inc. (NASDAQ:ALMR) released its earnings results on Wednesday, November, 4th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.03. The company had revenue of $33.55 million for the quarter. Alamar Biosciences had a negative trailing twelve-month return on equity of 78.71% and a negative net margin of 48.22%. Read the conference call transcript. When did Alamar Biosciences IPO? Alamar Biosciences (ALMR) raised $180 million in an IPO on Friday, April 17th 2026. The company issued 11,250,000 shares at $15.00-$17.00 per share. When did Alamar Biosciences' lock-up period expire? Alamar Biosciences's lock-up period expired on Wednesday, October 14th. Alamar Biosciences had issued 11,250,000 shares in its public offering on April 17th. The total size of the offering was $191,250,000 based on an initial share price of $17.00. Since the expiration of Alamar Biosciences' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted. Who are Alamar Biosciences' major shareholders? Alamar Biosciences' top institutional investors include State Street Corp (0.37%), Goldman Sachs Group Inc. (0.19%), Sumitomo Mitsui Trust Group Inc. (0.10%) and Bellevue Group AG (0.05%). Insiders that own company stock include Nicholas Naclerio, Innovation Fund Gp Illumina II and Corporate Gp Vi Ltd Qiming. View institutional ownership trends. How do I buy shares of Alamar Biosciences? Shares of ALMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/04/2026Today11/20/2026Citi Annual Global Healthcare Conference 202612/02/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:ALMR CIK2104204 Webalamarbio.com Phone(510) 626-9888Fax510-605-5062Employees222Year Founded2018Price Target and Rating Average Price Target for Alamar Biosciences$33.00 High Price Target$36.00 Low Price Target$27.00 Potential Upside/Downside+15.1%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($2.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.82 million Net Margins-48.22% Pretax Margin-47.62% Return on Equity-78.71% Return on Assets-20.08% Debt Debt-to-Equity RatioN/A Current Ratio9.49 Quick Ratio7.87 Sales & Book Value Annual Sales$74.21 million Price / Sales26.85 Cash FlowN/A Price / Cash FlowN/A Book Value$4.37 per share Price / Book6.56Miscellaneous Outstanding Shares69,480,000Free FloatN/AMarket Cap$1.99 billion OptionableN/A BetaN/A Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:ALMR) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alamar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alamar Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.